REGN vs. RVTY: Regeneron Pharmaceuticals vs. Revvity Stock Comparison

November 11, 2026

How do Regeneron Pharmaceuticals (REGN) and Revvity (RVTY) stack up? This page sets them side by side across company profile, performance and risk, profitability, growth, financial strength, dividends, and valuation, with selected fundamentals also measured against each stock's industry-group peers.

Company Profile

Regeneron Pharmaceuticals (REGN) and Revvity (RVTY) both fall under the Pharmaceuticals, Biotechnology & Life Sciences industry group, but REGN is classified in Biotechnology while RVTY is classified in Life Sciences Tools & Services.

Company profile comparison for Regeneron Pharmaceuticals (REGN) and Revvity (RVTY)
Profile Item	REGN	RVTY
Name	Regeneron Pharmaceuticals, Inc.	Revvity Inc.
Country/Region	United States	United States
GICS Sector	Health Care	Health Care
GICS Industry Group	Pharmaceuticals, Biotechnology & Life Sciences	Pharmaceuticals, Biotechnology & Life Sciences
GICS Industry	Biotechnology	Life Sciences Tools & Services
GICS Sub-Industry	Biotechnology	Life Sciences Tools & Services
Market Capitalization	93.55 billion USD	17.31 billion USD
Currency	USD	USD
Exchange	Nasdaq	NYSE
Listing Date	April 2, 1991	February 21, 1973
Security Type	Common Stock	Common Stock

Price Performance

Cumulative Growth

REGN

RVTY

GSPC

Regeneron Pharmaceuticals (REGN) vs. Revvity (RVTY), with S&P 500 (GSPC) for reference: Growth of a $10,000 investment over the past five years. Adjusted for dividends and splits.

Trailing Returns

Loading price history…

Trailing total returns for Regeneron Pharmaceuticals (REGN) and Revvity (RVTY). Returns over one year are annualized.

Calendar-Year Returns

Loading price history…

Calendar-year total returns for Regeneron Pharmaceuticals (REGN) and Revvity (RVTY). Each bar is that year's total return, measured year-end to year-end.

Performance Metrics

Price performance metrics for Regeneron Pharmaceuticals (REGN) and Revvity (RVTY)
Metric	REGN	RVTY
Total Return (1Y)	40.87%	76.75%
Total Return (3Y, Annualized)	5.15%	24.22%
Total Return (5Y, Annualized)	8.58%	-1.48%

Risk Profile

Drawdown History

REGN

RVTY

GSPC

Regeneron Pharmaceuticals (REGN) vs. Revvity (RVTY), with S&P 500 (GSPC) for reference: Drawdown from the running peak over the past five years. Each line shows the decline from its prior peak; 0% marks a new high.

Return Distribution

Loading price history…

Distribution of monthly total returns for Regeneron Pharmaceuticals (REGN) and Revvity (RVTY). Each bar is the share of months whose return fell in that 5% bucket.

Risk Metrics

Risk profile metrics for Regeneron Pharmaceuticals (REGN) and Revvity (RVTY)
Metric	REGN	RVTY
Volatility (1Y, Annualized)	34.08%	40.22%
Beta (5Y)	0.10	1.07
Max Drawdown (5Y)	-59.69%	-59.01%
Avg. Volume (3M)	772.95K	1.89M

Risk-Adjusted Performance

Risk-Return Positioning

REGN and RVTY are plotted by 1-year volatility (risk) and 1-year return. The dashed Capital Allocation Line runs from the risk-free rate through the shared industry median.

Risk-Adjusted Metrics

Risk-adjusted metrics for Regeneron Pharmaceuticals (REGN) and Revvity (RVTY)
Metric	REGN	RVTY
Sharpe Ratio (1Y)	1.07	1.80
Sortino Ratio (1Y)	1.70	2.90

Profitability

ROE (TTM)

Regeneron Pharmaceuticals (REGN) at 14.95% sits in the top ROE quartile, while Revvity (RVTY) at 3.45% is closer to the peer norm — stronger capital efficiency for REGN.

REGN

Pharmaceuticals, Biotechnology & Life Sciences industry group

14.95%

Max: 109.18%
REGN: 14.95%
Q3: 6.23%
Median: -26.66%
Q1: -64.05%
Min: -167.77%

RVTY

Pharmaceuticals, Biotechnology & Life Sciences industry group

3.45%

Max: 109.18%
Q3: 6.23%
RVTY: 3.45%
Median: -26.66%
Q1: -64.05%
Min: -167.77%

Regeneron Pharmaceuticals (REGN) vs. Revvity (RVTY): A comparison of their ROE against the Pharmaceuticals, Biotechnology & Life Sciences industry group benchmark.

Net Margin (TTM)

Regeneron Pharmaceuticals (REGN) at 28.51% keeps the most of each sales dollar — above its industry’s net margin range — and Revvity (RVTY) at 8.61% also retains a top-quartile share.

REGN

Pharmaceuticals, Biotechnology & Life Sciences industry group

28.51%

REGN: 28.51%
Max: 18.05%
Q3: 4.78%
Median: 0.00%
Q1: -4.14%
Min: -17.05%

RVTY

Pharmaceuticals, Biotechnology & Life Sciences industry group

8.61%

Max: 18.05%
RVTY: 8.61%
Q3: 4.78%
Median: 0.00%
Q1: -4.14%
Min: -17.05%

Regeneron Pharmaceuticals (REGN) vs. Revvity (RVTY): A comparison of their net margin against the Pharmaceuticals, Biotechnology & Life Sciences industry group benchmark.

Operating Margin (TTM)

Both Regeneron Pharmaceuticals (REGN) at 40.46% and Revvity (RVTY) at 17.06% convert sales into operating profit at a top-quartile rate, pointing to tighter cost discipline before financing and tax.

REGN

Pharmaceuticals, Biotechnology & Life Sciences industry group

40.46%

Max: 83.12%
REGN: 40.46%
Q3: 14.77%
Median: 0.00%
Q1: -78.82%
Min: -207.40%

RVTY

Pharmaceuticals, Biotechnology & Life Sciences industry group

17.06%

Max: 83.12%
RVTY: 17.06%
Q3: 14.77%
Median: 0.00%
Q1: -78.82%
Min: -207.40%

Regeneron Pharmaceuticals (REGN) vs. Revvity (RVTY): A comparison of their operating margin against the Pharmaceuticals, Biotechnology & Life Sciences industry group benchmark.

Profitability Metrics

Profitability metrics for Regeneron Pharmaceuticals (REGN) and Revvity (RVTY)
Metric	REGN	RVTY
ROE (TTM)	14.95%	3.45%
ROA (TTM)	7.59%	2.54%
Net Margin (TTM)	28.51%	8.61%
Operating Margin (TTM)	40.46%	17.06%
Gross Margin (TTM)	46.73%	55.91%

Growth

Revenue Growth

Both Regeneron Pharmaceuticals (REGN) at 0.99% and Revvity (RVTY) at 3.67% land near their industries' usual revenue growth ranges, so top-line momentum looks broadly in line with peers on both sides.

Regeneron Pharmaceuticals (REGN) vs. Revvity (RVTY): A comparison of their Revenue Growth across different time periods.

EPS Growth

Both Regeneron Pharmaceuticals (REGN) at 8.19% and Revvity (RVTY) at -5.91% land near their industries' usual EPS growth ranges, so bottom-line momentum looks broadly in line with peers on both sides.

Regeneron Pharmaceuticals (REGN) vs. Revvity (RVTY): A comparison of their EPS Growth across different time periods.

Growth Metrics

Growth metrics for Regeneron Pharmaceuticals (REGN) and Revvity (RVTY)
Metric	REGN	RVTY
Revenue Growth (YoY)	0.99%	3.67%
Revenue Growth (3Y CAGR)	5.62%	-4.82%
EPS Growth (YoY)	8.19%	-5.91%
EPS Growth (3Y CAGR)	2.77%	-23.26%

Financial Strength

Current Ratio (MRQ)

Both Regeneron Pharmaceuticals (REGN) at 3.35 and Revvity (RVTY) at 2.65 carry current ratio within their industries’ typical mid-ranges, suggesting balanced short-term liquidity relative to peers.

REGN

Pharmaceuticals, Biotechnology & Life Sciences industry group

3.35

Max: 25.13
Q3: 12.13
Median: 5.52
REGN: 3.35
Q1: 2.47
Min: 0.10

RVTY

Pharmaceuticals, Biotechnology & Life Sciences industry group

2.65

Max: 25.13
Q3: 12.13
Median: 5.52
RVTY: 2.65
Q1: 2.47
Min: 0.10

Regeneron Pharmaceuticals (REGN) vs. Revvity (RVTY): A comparison of their current ratio against the Pharmaceuticals, Biotechnology & Life Sciences industry group benchmark.

Debt / Equity (MRQ)

Both Regeneron Pharmaceuticals (REGN) at 0.08 and Revvity (RVTY) at 0.38 fund their balance sheets with roughly industry-typical debt-to-equity mixes.

REGN

Pharmaceuticals, Biotechnology & Life Sciences industry group

0.08

Max: 1.42
Q3: 0.65
Median: 0.15
REGN: 0.08
Q1: 0.02
Min: 0.00

RVTY

Pharmaceuticals, Biotechnology & Life Sciences industry group

0.38

Max: 1.42
Q3: 0.65
RVTY: 0.38
Median: 0.15
Q1: 0.02
Min: 0.00

Regeneron Pharmaceuticals (REGN) vs. Revvity (RVTY): A comparison of their debt-to-equity ratio against the Pharmaceuticals, Biotechnology & Life Sciences industry group benchmark.

Financial Strength Metrics

Financial strength metrics for Regeneron Pharmaceuticals (REGN) and Revvity (RVTY)
Metric	REGN	RVTY
Current Ratio (MRQ)	3.35	2.65
Debt / Equity (MRQ)	0.08	0.38
Net Debt / EBITDA	-1.17	2.43

Dividends

Dividend Yield (TTM)

Both Regeneron Pharmaceuticals (REGN) at 0.41% and Revvity (RVTY) at 0.19% yield above their industries’ entire benchmark ranges — high enough that dividend safety, not income, becomes the first question.

REGN

Pharmaceuticals, Biotechnology & Life Sciences industry group

0.41%

REGN: 0.41%
Max: 0.00%
Q3: 0.00%
Median: 0.00%
Q1: 0.00%
Min: 0.00%

RVTY

Pharmaceuticals, Biotechnology & Life Sciences industry group

0.19%

RVTY: 0.19%
Max: 0.00%
Q3: 0.00%
Median: 0.00%
Q1: 0.00%
Min: 0.00%

Regeneron Pharmaceuticals (REGN) vs. Revvity (RVTY): A comparison of their dividend yield against the Pharmaceuticals, Biotechnology & Life Sciences industry group benchmark.

Dividend Payout Ratio (TTM)

Both Regeneron Pharmaceuticals (REGN) at 8.18% and Revvity (RVTY) at 13.40% pay out more of their earnings than any of their industry peers — the thinnest cover in their groups, so dividend headroom deserves attention.

REGN

Pharmaceuticals, Biotechnology & Life Sciences industry group

8.18%

REGN: 8.18%
Max: 0.00%
Q3: 0.00%
Median: 0.00%
Q1: 0.00%
Min: 0.00%

RVTY

Pharmaceuticals, Biotechnology & Life Sciences industry group

13.40%

RVTY: 13.40%
Max: 0.00%
Q3: 0.00%
Median: 0.00%
Q1: 0.00%
Min: 0.00%

Regeneron Pharmaceuticals (REGN) vs. Revvity (RVTY): A comparison of their payout ratio against the Pharmaceuticals, Biotechnology & Life Sciences industry group benchmark.

Dividend Metrics

Dividend metrics for Regeneron Pharmaceuticals (REGN) and Revvity (RVTY)
Metric	REGN	RVTY
Dividend Yield (TTM)	0.41%	0.19%
Dividend Payout Ratio (TTM)	8.18%	13.40%

Valuation

P/E Ratio (TTM)

Regeneron Pharmaceuticals (REGN) at 19.99 is near its industry’s usual P/E ratio, while Revvity (RVTY) at 68.94 sits in the richer quartile — RVTY needs stronger growth or earnings quality to justify the premium.

REGN

Pharmaceuticals, Biotechnology & Life Sciences industry group

19.99

Max: 85.34
Q3: 43.46
Median: 26.69
REGN: 19.99
Q1: 13.30
Min: 0.07

RVTY

Pharmaceuticals, Biotechnology & Life Sciences industry group

68.94

Max: 85.34
RVTY: 68.94
Q3: 43.46
Median: 26.69
Q1: 13.30
Min: 0.07

Regeneron Pharmaceuticals (REGN) vs. Revvity (RVTY): A comparison of their P/E ratio against the Pharmaceuticals, Biotechnology & Life Sciences industry group benchmark.

P/S Ratio (TTM)

On P/S ratio, both Regeneron Pharmaceuticals (REGN) at 5.54 and Revvity (RVTY) at 5.88 are priced roughly in line with their industries — neither looks cheap nor rich on a sales basis.

REGN

Pharmaceuticals, Biotechnology & Life Sciences industry group

5.54

Max: 58.18
Q3: 25.77
Median: 7.30
REGN: 5.54
Q1: 3.01
Min: 0.01

RVTY

Pharmaceuticals, Biotechnology & Life Sciences industry group

5.88

Max: 58.18
Q3: 25.77
Median: 7.30
RVTY: 5.88
Q1: 3.01
Min: 0.01

Regeneron Pharmaceuticals (REGN) vs. Revvity (RVTY): A comparison of their P/S ratio against the Pharmaceuticals, Biotechnology & Life Sciences industry group benchmark.

P/B Ratio (MRQ)

On P/B ratio, both Regeneron Pharmaceuticals (REGN) at 2.71 and Revvity (RVTY) at 2.39 are valued close to their industries’ norm against book — neither stands out from peers.

REGN

Pharmaceuticals, Biotechnology & Life Sciences industry group

2.71

Max: 13.53
Q3: 6.54
Median: 3.25
REGN: 2.71
Q1: 1.69
Min: -5.59

RVTY

Pharmaceuticals, Biotechnology & Life Sciences industry group

2.39

Max: 13.53
Q3: 6.54
Median: 3.25
RVTY: 2.39
Q1: 1.69
Min: -5.59

Regeneron Pharmaceuticals (REGN) vs. Revvity (RVTY): A comparison of their P/B ratio against the Pharmaceuticals, Biotechnology & Life Sciences industry group benchmark.

Valuation Metrics

Valuation metrics for Regeneron Pharmaceuticals (REGN) and Revvity (RVTY)
Metric	REGN	RVTY
P/E Ratio (TTM)	19.99	68.94
P/S Ratio (TTM)	5.54	5.88
P/B Ratio (MRQ)	2.71	2.39
Free Cash Flow Yield (TTM)	2.76%	3.62%